<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02546765</url>
  </required_header>
  <id_info>
    <org_study_id>2014P000413</org_study_id>
    <nct_id>NCT02546765</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine and IV Acetaminophen for the Prevention of Postoperative Delirium Following Cardiac Surgery</brief_title>
  <acronym>DEXACET</acronym>
  <official_title>Dexmedetomidine and IV Acetaminophen for the Prevention of Postoperative Delirium Following Cardiac Surgery in Adult Patients 60 Years of Age and Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators will assess the incidence and duration of postoperative delirium in patients
      ≥60 years old undergoing coronary artery bypass grafting (CABG), with/without valve surgery
      (aortic and/or mitral) based on different regimens for postoperative sedation and analgesia.
      Patients will receive either intravenous (IV) dexmedetomidine and IV acetaminophen or
      standard postoperative management using IV propofol with morphine or hydromorphone. The
      Confusion Assessment Method (CAM) will be used to assess delirium in these patients.
      Investigators also seek to compare postoperative (48 hours) analgesic requirements in
      patients with or without IV acetaminophen. Investigators will finally assess postoperative
      cognition in post-surgical patients up to one year post-discharge using a cognitive
      assessment scale.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, placebo-controlled, triple-blinded, factorial design study
      consisting of 120 patients who were randomized and received a study intervention. Intravenous
      dexmedetomidine and acetaminophen will be compared to the standard sedation/analgesic
      propofol and opioid regimen.

      After obtaining informed consent, study subjects will be randomized by an unblinded
      investigator and receive a specific combination of both sedatives and analgesic medications.
      Sedatives will include either IV propofol or IV dexmedetomidine, and analgesics IV
      acetaminophen or placebo (100 mL 0.9% NaCl equivalent to the administered volume of IV
      acetaminophen). Subjects will be allocated in a 1:1:1:1 fashion into the following four
      treatment arms: 1. IV acetaminophen with IV propofol, 2. IV acetaminophen with IV
      dexmedetomidine, 3. IV propofol with placebo, or 4. IV dexmedetomidine with placebo. Sedation
      and analgesia protocols will begin while patients are in the OR and continue as they are
      transferred to the Cardiovascular Intensive Care Unit (CVICU). The medications for sedation
      will be weight based (loading infusion of 0.5 - 1 µg/kg given over 10 minutes followed by a
      maintenance infusion of 0.1-1.4 µg/kg/hr for IV dexmedetomidine, or 20-100 µg/kg/min for IV
      propofol). Postoperative sedation is administrated 4-6 hours before patients are woken up in
      the CVICU. IV Acetaminophen (1g or 100mL) will be given every 6 hours for 48 hours to
      patients randomized to this drug. The volume of the placebo will be administered in
      respective groups in the same timeframe. Oral acetaminophen will be continued until discharge
      in all patients. All groups will also receive bolus doses of opioids (IV morphine or
      hydromorphone) as needed for breakthrough pain.

      Patients will be administered a preoperative (baseline) and a series of post-operative
      evaluations to assess delirium by a blinded investigator. Baseline assessments will include
      the Montreal Cognitive Assessment (MoCA), days of the week (DOW), months of the year (MOY),
      Delirium Symptom Interview (DSI), the Geriatric Depression Scale (GDS) and the Confusion
      Assessment Method (CAM). Daily cognitive assessments will include the DSI, CAM, and a
      standard cognitive assessment. At discharge, the MoCA, DOW, MOY, DSI, and CAM will be given.
      Follow-up assessments will be conducted at 1 month and 1 year post-discharge and will include
      the telephonic MoCA, DSI, GDS and CAM. The delirium research assessments will not be provided
      to the treating clinicians. Treating clinicians will assess and treat delirium as usual,
      including assessment and correction of reversible causes, behavioral management, and use of
      IV haloperidol as needed for agitation. Rescue doses of haloperidol will be recorded in the
      study.

      Blood will be collected from all subjects at the time of the baseline assessment,
      post-operation day 1 (POD1) while in ICU, POD 2 in the ICU, and within 48 hours of discharge.
      Two sets of 10 mL will be collected at each time point, with a total of 80mL of blood per
      patient. Efforts will be made to efficiently draw blood through the patient's arterial line
      at baseline or add onto to scheduled draws with phlebotomy. The plasma and buffy coat will be
      separated from the blood, aliquoted into labeled vials, and stored in a biomarker bank at
      -80°C for future use.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Actual">July 2019</completion_date>
  <primary_completion_date type="Actual">May 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Delirium</measure>
    <time_frame>Participants will be followed for the duration of the hospital stay, an average of 5 days</time_frame>
    <description>Incidence of delirium will be analyzed between patients treated with and without IV acetaminophen, measured from 24 hours post-operation and daily until discharge. Delirium will be defined as an acute change in pre-operative baseline condition with additional features of inattention and either disorganized thinking and altered loss of consciousness, as defined by the Confusion Assessment Method (CAM).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Delirium</measure>
    <time_frame>Participants will be followed for the duration of the hospital stay, an average of 6 days, and at 1 month and 1- year following the date of surgery</time_frame>
    <description>Duration of delirium will be analyzed, measured from 24 hours post-operation and daily until discharge. Additional measurements will be made at 1 month and 1 year after discharge. Delirium will be defined as an acute change in pre-operative baseline condition with additional features of inattention and either disorganized thinking and altered loss of consciousness, as defined by the Confusion Assessment Method (CAM).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Delirium</measure>
    <time_frame>Participants will be followed for the duration of the hospital stay, an average of 6 days</time_frame>
    <description>Severity of delirium will be analyzed, measured from 24 hours post-operation and daily until discharge. The worst severity experienced while in the hospital will be analyzed. Delirium will be defined as an acute change in pre-operative baseline condition with additional features of inattention and either disorganized thinking and altered loss of consciousness, as defined by the Confusion Assessment Method Severity Score (CAM-S, Confusion Assessment Method-Severity). range 0 [best/no delirium] to 19 [worst]; Minimal Clinical Important Difference (MCID) 2 points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Opioid Consumption in Morphine Equivalents</measure>
    <time_frame>Participants will be followed for the first 48 hours postoperatively.</time_frame>
    <description>Defined by the amount of additional opioid (IV morphine or hydromorphone) and oral acetaminophen medications required in the first 48 hours postoperatively. Values will be converted to morphine equivalents for analysis. Total morphine equivalent is calculated as the sum of (fentanyl dose x 100)+(hydromorphone dose x 4)+morphine dose+(oxycodone dose x 1.5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment (MoCA)</measure>
    <time_frame>On the day of discharge, an average of 6 days</time_frame>
    <description>MoCA scores at discharge will be reported in order to assess the occurrence of postoperative cognitive decline. Blinded study staff trained in administering the assessments will collect the data. MoCA is scored on a scale from 0 [worst] to 30 [best]; ǂA MoCA score of 24 would be equivalent to an Mini-Mental State Examination (MMSE) of about 27 or 28. Depending on education and peak intellectual attainment, such a score could be consistent with being either cognitively normal, or having very early mild cognitive impairment. Certainly such a person would be capable of living independently in the community and managing most or all of their affairs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of Stay</measure>
    <time_frame>Measured in days admitted in the hospital, an average of 6 days</time_frame>
    <description>Defined by the number of days admitted in the hospital following the completion of surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU Length of Stay</measure>
    <time_frame>Measured in days admitted in the ICU, an average of 2 days</time_frame>
    <description>Defined by the number of days admitted in the ICU prior to transfer to the general cardiac surgical floor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow up Incidence of Cognitive Dysfunction</measure>
    <time_frame>Patients will be assessed for cognitive dysfunction with T-MOCA at 1 month following the date of surgery</time_frame>
    <description>The follow up incidence of cognitive dysfunction will be analyzed at 1 month after discharge. T-MoCA is Telephone Montreal Cognitive Assessment Scale (MOCA). The T-MoCA is scored out of 22. The minimum score is 0 (worst) and maximum score is 22 (best). T-MOCA is converted back to 30 (full MOCA) with the help of conversion algorithms to a full MOCA.Example: 19/22 converts back to 30 by performing the following equation: (19×30) ÷ 22. The total converted score is 25.9 or 26/30 which is considered in the normal range.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Delirium</condition>
  <arm_group>
    <arm_group_label>IV acetaminophen &amp; IV propofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20-100 µg/kg/min IV propofol given for 4-6 hours before the patients are woken up in the ICU
1g IV acetaminophen every 6 hours for 48 hours during the first 2 days postoperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV acetaminophen &amp; IV dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A loading infusion of 0.5 - 1 µg/kg given over 10 minutes will be administered. After the loading infusion, a maintenance infusion of 0.1-1.4 µg/kg/hr will be initiated.
1 g IV acetaminophen every 6 hours for 48 hours during the first 2 days postoperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV propofol &amp; placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20-100 µg/kg/min IV propofol given for 4-6 hours before the patients are woken up in the ICU Volume of the placebo (saline) will match that of IV acetaminophen at 100ml 0.9% NaCl.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV dexmedetomidine &amp; placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.1-1.0 µg/kg/hour IV dexmedetomidine given for 4-6 hours before the patients are woken up in the ICU Volume of the placebo (saline) will match that of i.v. acetaminophen at 100ml 0.9% NaCl.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV acetaminophen &amp; IV propofol</intervention_name>
    <description>use of IV tylenol and IV propofol for pain and sedation (respectively)</description>
    <arm_group_label>IV acetaminophen &amp; IV propofol</arm_group_label>
    <other_name>Ofirmev</other_name>
    <other_name>Diprivan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV acetaminophen &amp; IV dexmedetomidine</intervention_name>
    <description>use of IV tylenol and IV dexmedetomidine for pain and sedation (respectively)</description>
    <arm_group_label>IV acetaminophen &amp; IV dexmedetomidine</arm_group_label>
    <other_name>Ofirmev</other_name>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV propofol &amp; placebo</intervention_name>
    <description>use of IV propofol for sedation and morphine, the drug of choice for cardiac pain</description>
    <arm_group_label>IV propofol &amp; placebo</arm_group_label>
    <other_name>Diprivan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV dexmedetomidine &amp; placebo</intervention_name>
    <description>use of IV dexmedetomidine for sedation and morphine, the drug of choice for cardiac pain</description>
    <arm_group_label>IV dexmedetomidine &amp; placebo</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥ 60 years of age

          -  Undergoing CABG with/without valve (aortic and/or mitral) procedure requiring bypass

        Exclusion Criteria:

          -  Pre-operative Left Ventricular Ejection Fraction (LVEF) &lt; 30%

          -  Emergent or urgent procedures, aortic surgery

          -  Pre-existing cognitive impairment (defined based on a short screening assessment),
             Parkinson's disease, Alzheimer's disease, recent seizures (&lt;3 months)

          -  Prophylactic medications for cognitive decline

          -  Serum creatinine &gt; 2 mg/dl

          -  Liver dysfunction (liver enzymes &gt; 4x the baseline, since patients will have a
             baseline liver function tests), history and exam suggestive of jaundice

          -  Known history of alcohol or drug abuse (&gt;10 drinks per week)

          -  Hypersensitivity to any of the study drug and percutaneous procedures

          -  Non-English speaking
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Balachundhar Subramaniam, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rudolph JL, Jones RN, Levkoff SE, Rockett C, Inouye SK, Sellke FW, Khuri SF, Lipsitz LA, Ramlawi B, Levitsky S, Marcantonio ER. Derivation and validation of a preoperative prediction rule for delirium after cardiac surgery. Circulation. 2009 Jan 20;119(2):229-36. doi: 10.1161/CIRCULATIONAHA.108.795260. Epub 2008 Dec 31.</citation>
    <PMID>19118253</PMID>
  </reference>
  <reference>
    <citation>Inouye SK. Delirium in older persons. N Engl J Med. 2006 Mar 16;354(11):1157-65. Review. Erratum in: N Engl J Med. 2006 Apr 13;354(15):1655.</citation>
    <PMID>16540616</PMID>
  </reference>
  <reference>
    <citation>Saczynski JS, Marcantonio ER, Quach L, Fong TG, Gross A, Inouye SK, Jones RN. Cognitive trajectories after postoperative delirium. N Engl J Med. 2012 Jul 5;367(1):30-9. doi: 10.1056/NEJMoa1112923.</citation>
    <PMID>22762316</PMID>
  </reference>
  <reference>
    <citation>Lin YY, He B, Chen J, Wang ZN. Can dexmedetomidine be a safe and efficacious sedative agent in post-cardiac surgery patients? a meta-analysis. Crit Care. 2012 Sep 27;16(5):R169. doi: 10.1186/cc11646.</citation>
    <PMID>23016926</PMID>
  </reference>
  <reference>
    <citation>Corbett SM, Rebuck JA, Greene CM, Callas PW, Neale BW, Healey MA, Leavitt BJ. Dexmedetomidine does not improve patient satisfaction when compared with propofol during mechanical ventilation. Crit Care Med. 2005 May;33(5):940-5.</citation>
    <PMID>15891317</PMID>
  </reference>
  <reference>
    <citation>Shehabi Y, Grant P, Wolfenden H, Hammond N, Bass F, Campbell M, Chen J. Prevalence of delirium with dexmedetomidine compared with morphine based therapy after cardiac surgery: a randomized controlled trial (DEXmedetomidine COmpared to Morphine-DEXCOM Study). Anesthesiology. 2009 Nov;111(5):1075-84. doi: 10.1097/ALN.0b013e3181b6a783.</citation>
    <PMID>19786862</PMID>
  </reference>
  <reference>
    <citation>Maldonado JR, Wysong A, van der Starre PJ, Block T, Miller C, Reitz BA. Dexmedetomidine and the reduction of postoperative delirium after cardiac surgery. Psychosomatics. 2009 May-Jun;50(3):206-17. doi: 10.1176/appi.psy.50.3.206.</citation>
    <PMID>19567759</PMID>
  </reference>
  <reference>
    <citation>Dasta JF, Jacobi J, Sesti AM, McLaughlin TP. Addition of dexmedetomidine to standard sedation regimens after cardiac surgery: an outcomes analysis. Pharmacotherapy. 2006 Jun;26(6):798-805.</citation>
    <PMID>16716133</PMID>
  </reference>
  <reference>
    <citation>Holmér Pettersson P, Jakobsson J, Owall A. Plasma concentrations following repeated rectal or intravenous administration of paracetamol after heart surgery. Acta Anaesthesiol Scand. 2006 Jul;50(6):673-7.</citation>
    <PMID>16987360</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 13, 2015</study_first_submitted>
  <study_first_submitted_qc>September 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2015</study_first_posted>
  <results_first_submitted>November 14, 2019</results_first_submitted>
  <results_first_submitted_qc>December 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 7, 2020</results_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Balachundhar Subramaniam</investigator_full_name>
    <investigator_title>Anesthesiologist</investigator_title>
  </responsible_party>
  <keyword>analgesics</keyword>
  <keyword>cardiac surgery</keyword>
  <keyword>sedation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 29, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT02546765/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>After signing the informed consent, 19 withdrew prior to randomization. (8 patient withdrawals, 8 found ineligible, 1 withdrawn because of inappropriate behavior and emotional lability, 1 withdrawn after entering and receiving intervention in another trial, 1 withdrawn because of inability to complete baseline assessment for same-day admission)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>IV Acetaminophen &amp; IV Propofol</title>
          <description>20-100 µg/kg/min IV propofol given for 4-6 hours before the patients are woken up in the ICU
1g IV acetaminophen every 6 hours for 48 hours during the first 2 days postoperatively
IV acetaminophen &amp; IV propofol: use of IV tylenol and IV propofol for pain and sedation (respectively)</description>
        </group>
        <group group_id="P2">
          <title>IV Acetaminophen &amp; IV Dexmedetomidine</title>
          <description>A loading infusion of 0.5 - 1 µg/kg given over 10 minutes will be administered. After the loading infusion, a maintenance infusion of 0.1-1.4 µg/kg/hr will be initiated.
1 g IV acetaminophen every 6 hours for 48 hours during the first 2 days postoperatively
IV acetaminophen &amp; IV dexmedetomidine: use of IV tylenol and IV dexmedetomidine for pain and sedation (respectively)</description>
        </group>
        <group group_id="P3">
          <title>IV Propofol &amp; Placebo</title>
          <description>20-100 µg/kg/min IV propofol given for 4-6 hours before the patients are woken up in the ICU Volume of the placebo (saline) will match that of IV acetaminophen at 100ml 0.9% NaCl.
IV propofol &amp; placebo: use of IV propofol for sedation and morphine, the drug of choice for cardiac pain</description>
        </group>
        <group group_id="P4">
          <title>IV Dexmedetomidine &amp; Placebo</title>
          <description>0.1-1.0 µg/kg/hour IV dexmedetomidine given for 4-6 hours before the patients are woken up in the ICU Volume of the placebo (saline) will match that of i.v. acetaminophen at 100ml 0.9% NaCl.
IV dexmedetomidine &amp; placebo: use of IV dexmedetomidine for sedation and morphine, the drug of choice for cardiac pain</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="29">29 Received study drug; 1 withdrew before surgery and after randomization</participants>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Acetaminophen-Propofol</title>
          <description>Received Intravenous Acetaminophen 6 hourly for 8 doses and intravenous Propofol as sedative until extubation</description>
        </group>
        <group group_id="B2">
          <title>Acetaminophen-Dexmedetomidine</title>
          <description>Received Intravenous Acetaminophen 6 hourly for 8 doses and intravenous dexmedetomidine as sedative until extubation</description>
        </group>
        <group group_id="B3">
          <title>Placebo-Propofol</title>
          <description>Received Intravenous Placebo 6 hourly for 8 doses and Intravenous Propofol as a sedative until extubation</description>
        </group>
        <group group_id="B4">
          <title>Placebo-Dexmedetomidine</title>
          <description>Received Intravenous Placebo 6 hourly for 8 doses and Intravenous Dexmedetomidine as a sedative until extubation</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="30"/>
            <count group_id="B4" value="30"/>
            <count group_id="B5" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70" lower_limit="66" upper_limit="75"/>
                    <measurement group_id="B2" value="64" lower_limit="63" upper_limit="72"/>
                    <measurement group_id="B3" value="71" lower_limit="64" upper_limit="79"/>
                    <measurement group_id="B4" value="69" lower_limit="63" upper_limit="74"/>
                    <measurement group_id="B5" value="69" lower_limit="63" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="116"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="111"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84.1" lower_limit="79" upper_limit="93.2"/>
                    <measurement group_id="B2" value="89.1" lower_limit="80.4" upper_limit="102"/>
                    <measurement group_id="B3" value="90" lower_limit="75.8" upper_limit="107"/>
                    <measurement group_id="B4" value="87.6" lower_limit="82" upper_limit="102"/>
                    <measurement group_id="B5" value="87" lower_limit="79.15" upper_limit="100.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cms</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170.2" lower_limit="167.6" upper_limit="173.3"/>
                    <measurement group_id="B2" value="173" lower_limit="167.6" upper_limit="180.3"/>
                    <measurement group_id="B3" value="175.1" lower_limit="167.6" upper_limit="180"/>
                    <measurement group_id="B4" value="172.7" lower_limit="167.6" upper_limit="178"/>
                    <measurement group_id="B5" value="172.7" lower_limit="167.6" upper_limit="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.5" lower_limit="26.6" upper_limit="32.3"/>
                    <measurement group_id="B2" value="29.7" lower_limit="26.6" upper_limit="32.3"/>
                    <measurement group_id="B3" value="29.2" lower_limit="25.9" upper_limit="34.3"/>
                    <measurement group_id="B4" value="29.4" lower_limit="27" upper_limit="32"/>
                    <measurement group_id="B5" value="29.44" lower_limit="26.53" upper_limit="32.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Surgical Characteristics-</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>CABG surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CABG+mitral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CABG+aortic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of arteries affected</title>
          <units>arteries</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3" lower_limit="2" upper_limit="3"/>
                    <measurement group_id="B2" value="3" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="B3" value="3" lower_limit="2" upper_limit="3"/>
                    <measurement group_id="B4" value="3" lower_limit="2" upper_limit="3"/>
                    <measurement group_id="B5" value="3" lower_limit="2" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Preoperative statin use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cross-clamp time</title>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78" lower_limit="66" upper_limit="87"/>
                    <measurement group_id="B2" value="67" lower_limit="58" upper_limit="84"/>
                    <measurement group_id="B3" value="64" lower_limit="54" upper_limit="96"/>
                    <measurement group_id="B4" value="73" lower_limit="60" upper_limit="93"/>
                    <measurement group_id="B5" value="75" lower_limit="59" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Delirium</title>
        <description>Incidence of delirium will be analyzed between patients treated with and without IV acetaminophen, measured from 24 hours post-operation and daily until discharge. Delirium will be defined as an acute change in pre-operative baseline condition with additional features of inattention and either disorganized thinking and altered loss of consciousness, as defined by the Confusion Assessment Method (CAM).</description>
        <time_frame>Participants will be followed for the duration of the hospital stay, an average of 5 days</time_frame>
        <population>This is a 2 x 2 cross over study.</population>
        <group_list>
          <group group_id="O1">
            <title>Acetaminophen and Dexmedetomidine</title>
            <description>Patients who received intravenous Acetaminophen for analgesia and dexmedetomidine for sedation</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen and Propofol</title>
            <description>Those who received IV acetaminophen for analgesia and Propofol for sedation</description>
          </group>
          <group group_id="O3">
            <title>Placebo and Dexmedetomidine</title>
            <description>Those who received Placebo for analgesia and dexmedetomidine for sedation</description>
          </group>
          <group group_id="O4">
            <title>Placebo and Propofol</title>
            <description>Patients who received placebo for analgesia and Propofol for sedation</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Delirium</title>
          <description>Incidence of delirium will be analyzed between patients treated with and without IV acetaminophen, measured from 24 hours post-operation and daily until discharge. Delirium will be defined as an acute change in pre-operative baseline condition with additional features of inattention and either disorganized thinking and altered loss of consciousness, as defined by the Confusion Assessment Method (CAM).</description>
          <population>This is a 2 x 2 cross over study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Delirium</title>
        <description>Duration of delirium will be analyzed, measured from 24 hours post-operation and daily until discharge. Additional measurements will be made at 1 month and 1 year after discharge. Delirium will be defined as an acute change in pre-operative baseline condition with additional features of inattention and either disorganized thinking and altered loss of consciousness, as defined by the Confusion Assessment Method (CAM).</description>
        <time_frame>Participants will be followed for the duration of the hospital stay, an average of 6 days, and at 1 month and 1- year following the date of surgery</time_frame>
        <population>This is a 2 x 2 cross over study. Therefore, participants were analyzed for primary analgesic use (N=60 in each group)</population>
        <group_list>
          <group group_id="O1">
            <title>Acetaminophen and Dexmedetomidine</title>
            <description>Those who received Acetaminophen for analgesia and dexmedetomidine for sedation</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen and Propofol</title>
            <description>Those who received acetaminophen for analgesia and propofol for sedation</description>
          </group>
          <group group_id="O3">
            <title>Placebo and Dexmedetomidine</title>
            <description>Those who received placebo for analgesia and dexmedetomidine for sedation</description>
          </group>
          <group group_id="O4">
            <title>Placebo and Propofol</title>
            <description>Those who received Placebo for sedation and Propofol for analgesia</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Delirium</title>
          <description>Duration of delirium will be analyzed, measured from 24 hours post-operation and daily until discharge. Additional measurements will be made at 1 month and 1 year after discharge. Delirium will be defined as an acute change in pre-operative baseline condition with additional features of inattention and either disorganized thinking and altered loss of consciousness, as defined by the Confusion Assessment Method (CAM).</description>
          <population>This is a 2 x 2 cross over study. Therefore, participants were analyzed for primary analgesic use (N=60 in each group)</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O4" value="3" lower_limit="2" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Delirium</title>
        <description>Severity of delirium will be analyzed, measured from 24 hours post-operation and daily until discharge. The worst severity experienced while in the hospital will be analyzed. Delirium will be defined as an acute change in pre-operative baseline condition with additional features of inattention and either disorganized thinking and altered loss of consciousness, as defined by the Confusion Assessment Method Severity Score (CAM-S, Confusion Assessment Method-Severity). range 0 [best/no delirium] to 19 [worst]; Minimal Clinical Important Difference (MCID) 2 points</description>
        <time_frame>Participants will be followed for the duration of the hospital stay, an average of 6 days</time_frame>
        <population>This is a 2 x 2 cross over study. Therefore, participants were analyzed for primary analgesic use (N=60 in each group)</population>
        <group_list>
          <group group_id="O1">
            <title>Acetaminophen and Dexmedetomidine</title>
            <description>Those who received acetaminophen for analgesia and dexmedetomidine for sedation</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen and Propofol</title>
            <description>Those who received acetaminophen for analgesia and propofol for sedation</description>
          </group>
          <group group_id="O3">
            <title>Placebo and Dexmedetomidine</title>
            <description>Those who received placebo for analgesia and dexmedetomidine for sedation</description>
          </group>
          <group group_id="O4">
            <title>Placebo and Propofol</title>
            <description>Those who received placebo for analgesia and propofol for sedation</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Delirium</title>
          <description>Severity of delirium will be analyzed, measured from 24 hours post-operation and daily until discharge. The worst severity experienced while in the hospital will be analyzed. Delirium will be defined as an acute change in pre-operative baseline condition with additional features of inattention and either disorganized thinking and altered loss of consciousness, as defined by the Confusion Assessment Method Severity Score (CAM-S, Confusion Assessment Method-Severity). range 0 [best/no delirium] to 19 [worst]; Minimal Clinical Important Difference (MCID) 2 points</description>
          <population>This is a 2 x 2 cross over study. Therefore, participants were analyzed for primary analgesic use (N=60 in each group)</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="9" upper_limit="11"/>
                    <measurement group_id="O2" value="8" lower_limit="6" upper_limit="10"/>
                    <measurement group_id="O3" value="6" lower_limit="6" upper_limit="9"/>
                    <measurement group_id="O4" value="9" lower_limit="8" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Opioid Consumption in Morphine Equivalents</title>
        <description>Defined by the amount of additional opioid (IV morphine or hydromorphone) and oral acetaminophen medications required in the first 48 hours postoperatively. Values will be converted to morphine equivalents for analysis. Total morphine equivalent is calculated as the sum of (fentanyl dose x 100)+(hydromorphone dose x 4)+morphine dose+(oxycodone dose x 1.5)</description>
        <time_frame>Participants will be followed for the first 48 hours postoperatively.</time_frame>
        <population>This is a 2 x 2 cross over study.</population>
        <group_list>
          <group group_id="O1">
            <title>Acetaminophen and Dexmedetomidine</title>
            <description>Patients who received intravenous Acetaminophen for analgesia and dexmedetomidine for sedation</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen and Propofol</title>
            <description>Those who received acetaminophen for analgesia and propofol for sedation</description>
          </group>
          <group group_id="O3">
            <title>Placebo and Dexmedetomidine</title>
            <description>Those who received Placebo for analgesia and dexmedetomidine for sedation</description>
          </group>
          <group group_id="O4">
            <title>Placebo and Propofol</title>
            <description>Those who received placebo for analgesia and dexmedetomidine for sedation</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Opioid Consumption in Morphine Equivalents</title>
          <description>Defined by the amount of additional opioid (IV morphine or hydromorphone) and oral acetaminophen medications required in the first 48 hours postoperatively. Values will be converted to morphine equivalents for analysis. Total morphine equivalent is calculated as the sum of (fentanyl dose x 100)+(hydromorphone dose x 4)+morphine dose+(oxycodone dose x 1.5)</description>
          <population>This is a 2 x 2 cross over study.</population>
          <units>mcg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10050" lower_limit="5094" upper_limit="12530"/>
                    <measurement group_id="O2" value="12611" lower_limit="10026" upper_limit="17639"/>
                    <measurement group_id="O3" value="11382" lower_limit="10032" upper_limit="18840"/>
                    <measurement group_id="O4" value="12616" lower_limit="10116" upper_limit="22590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Montreal Cognitive Assessment (MoCA)</title>
        <description>MoCA scores at discharge will be reported in order to assess the occurrence of postoperative cognitive decline. Blinded study staff trained in administering the assessments will collect the data. MoCA is scored on a scale from 0 [worst] to 30 [best]; ǂA MoCA score of 24 would be equivalent to an Mini-Mental State Examination (MMSE) of about 27 or 28. Depending on education and peak intellectual attainment, such a score could be consistent with being either cognitively normal, or having very early mild cognitive impairment. Certainly such a person would be capable of living independently in the community and managing most or all of their affairs.</description>
        <time_frame>On the day of discharge, an average of 6 days</time_frame>
        <population>This is a 2 x 2 cross over study.</population>
        <group_list>
          <group group_id="O1">
            <title>Acetaminophen and Dexmedetomidine</title>
            <description>Patients who received intravenous Acetaminophen for analgesia and dexmedetomidine for sedation</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen and Propofol</title>
            <description>Those who received placebo for analgesia and propofol for sedation</description>
          </group>
          <group group_id="O3">
            <title>Placebo and Dexmedetomidine</title>
            <description>Those who received placebo for analgesia and dexmedetomidine for sedation</description>
          </group>
          <group group_id="O4">
            <title>Placebo and Propofol</title>
            <description>Those who received Placebo for analgesia and Propofol for sedation</description>
          </group>
        </group_list>
        <measure>
          <title>Montreal Cognitive Assessment (MoCA)</title>
          <description>MoCA scores at discharge will be reported in order to assess the occurrence of postoperative cognitive decline. Blinded study staff trained in administering the assessments will collect the data. MoCA is scored on a scale from 0 [worst] to 30 [best]; ǂA MoCA score of 24 would be equivalent to an Mini-Mental State Examination (MMSE) of about 27 or 28. Depending on education and peak intellectual attainment, such a score could be consistent with being either cognitively normal, or having very early mild cognitive impairment. Certainly such a person would be capable of living independently in the community and managing most or all of their affairs.</description>
          <population>This is a 2 x 2 cross over study.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="22" upper_limit="26"/>
                    <measurement group_id="O2" value="24" lower_limit="22" upper_limit="26"/>
                    <measurement group_id="O3" value="24" lower_limit="20" upper_limit="26"/>
                    <measurement group_id="O4" value="23" lower_limit="21" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Length of Stay</title>
        <description>Defined by the number of days admitted in the hospital following the completion of surgery.</description>
        <time_frame>Measured in days admitted in the hospital, an average of 6 days</time_frame>
        <population>This is a 2 x 2 cross over study.</population>
        <group_list>
          <group group_id="O1">
            <title>Acetaminophen and Dexmedetomidine</title>
            <description>Patients who received intravenous Acetaminophen for analgesia and dexmedetomidine for sedation</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen and Propofol</title>
            <description>Those who received acetaminophen for analgesia and propofol for sedation</description>
          </group>
          <group group_id="O3">
            <title>Placebo and Dexmedetomidine</title>
            <description>Those who received Placebo for analgesia and dexmedetomidine for sedation</description>
          </group>
          <group group_id="O4">
            <title>Placebo and Propofol</title>
            <description>Those who received placebo for analgesia and propofol for sedation</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Length of Stay</title>
          <description>Defined by the number of days admitted in the hospital following the completion of surgery.</description>
          <population>This is a 2 x 2 cross over study.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="6" upper_limit="9"/>
                    <measurement group_id="O2" value="8" lower_limit="6" upper_limit="11"/>
                    <measurement group_id="O3" value="9" lower_limit="7" upper_limit="11"/>
                    <measurement group_id="O4" value="8" lower_limit="6" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ICU Length of Stay</title>
        <description>Defined by the number of days admitted in the ICU prior to transfer to the general cardiac surgical floor</description>
        <time_frame>Measured in days admitted in the ICU, an average of 2 days</time_frame>
        <population>This is a 2 x 2 cross over study.</population>
        <group_list>
          <group group_id="O1">
            <title>Acetaminophen and Dexmedetomidine</title>
            <description>Patients who received intravenous Acetaminophen for analgesia and Dexmedetomidine for sedation</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen and Propofol</title>
            <description>Those who received acetaminophen for analgesia and propofol for sedation</description>
          </group>
          <group group_id="O3">
            <title>Placebo and Dexmedetomidine</title>
            <description>Those who received Placebo for analgesia and Dexmedetomidine for sedation</description>
          </group>
          <group group_id="O4">
            <title>Placebo and Propofol</title>
            <description>Those who received Placebo for analgesia and Propofol for sedation</description>
          </group>
        </group_list>
        <measure>
          <title>ICU Length of Stay</title>
          <description>Defined by the number of days admitted in the ICU prior to transfer to the general cardiac surgical floor</description>
          <population>This is a 2 x 2 cross over study.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8" lower_limit="24.9" upper_limit="43.5"/>
                    <measurement group_id="O2" value="30.3" lower_limit="25.3" upper_limit="52.8"/>
                    <measurement group_id="O3" value="49.1" lower_limit="29" upper_limit="92.9"/>
                    <measurement group_id="O4" value="29.3" lower_limit="25.7" upper_limit="74.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Follow up Incidence of Cognitive Dysfunction</title>
        <description>The follow up incidence of cognitive dysfunction will be analyzed at 1 month after discharge. T-MoCA is Telephone Montreal Cognitive Assessment Scale (MOCA). The T-MoCA is scored out of 22. The minimum score is 0 (worst) and maximum score is 22 (best). T-MOCA is converted back to 30 (full MOCA) with the help of conversion algorithms to a full MOCA.Example: 19/22 converts back to 30 by performing the following equation: (19×30) ÷ 22. The total converted score is 25.9 or 26/30 which is considered in the normal range.</description>
        <time_frame>Patients will be assessed for cognitive dysfunction with T-MOCA at 1 month following the date of surgery</time_frame>
        <population>Telephone (T)-MOCA at 1 month. This is a 2 x 2 cross over study.</population>
        <group_list>
          <group group_id="O1">
            <title>Acetaminophen and Dexmedetomidine</title>
            <description>Patients who received intravenous Acetaminophen for analgesia and dexmedetomidine for sedation</description>
          </group>
          <group group_id="O2">
            <title>Acetaminophen and Propofol</title>
            <description>Those who received acetaminophen for analgesia and propofol for sedation</description>
          </group>
          <group group_id="O3">
            <title>Placebo and Dexmedetomidine</title>
            <description>Those who received placebo for analgesia and dexmedetomidine for sedation</description>
          </group>
          <group group_id="O4">
            <title>Placebo and Propofol</title>
            <description>Those who received Placebo for analgesia and Propofol for sedation</description>
          </group>
        </group_list>
        <measure>
          <title>Follow up Incidence of Cognitive Dysfunction</title>
          <description>The follow up incidence of cognitive dysfunction will be analyzed at 1 month after discharge. T-MoCA is Telephone Montreal Cognitive Assessment Scale (MOCA). The T-MoCA is scored out of 22. The minimum score is 0 (worst) and maximum score is 22 (best). T-MOCA is converted back to 30 (full MOCA) with the help of conversion algorithms to a full MOCA.Example: 19/22 converts back to 30 by performing the following equation: (19×30) ÷ 22. The total converted score is 25.9 or 26/30 which is considered in the normal range.</description>
          <population>Telephone (T)-MOCA at 1 month. This is a 2 x 2 cross over study.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="16" upper_limit="20"/>
                    <measurement group_id="O2" value="18" lower_limit="16" upper_limit="20"/>
                    <measurement group_id="O3" value="19" lower_limit="17.5" upper_limit="21"/>
                    <measurement group_id="O4" value="18" lower_limit="16" upper_limit="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During hospital stay, an average of 7 days</time_frame>
      <desc>These were outcomes that are collected by the Society of Thoracic Surgery</desc>
      <group_list>
        <group group_id="E1">
          <title>Acetaminophen-Propofol</title>
          <description>Received Intravenous Acetaminophen 6 hourly for 8 doses and intravenous Propofol as sedative until extubation</description>
        </group>
        <group group_id="E2">
          <title>Acetaminophen-Dexmedetomidine</title>
          <description>Received Intravenous Acetaminophen 6 hourly for 8 doses and intravenous dexmedetomidine as sedative until extubation</description>
        </group>
        <group group_id="E3">
          <title>Placebo-Propofol</title>
          <description>Received Intravenous Placebo 6 hourly for 8 doses and Intravenous Propofol as a sedative until extubation</description>
        </group>
        <group group_id="E4">
          <title>Placebo-Dexmedetomidine</title>
          <description>Received Intravenous Placebo 6 hourly for 8 doses and Intravenous Dexmedetomidine as a sedative until extubation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>ICU hypotension</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Hypotension during the ICU admission</description>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="31"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="29"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E4" events="14" subjects_affected="14" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title vocab="ICU bradycardia">Bradycardia</sub_title>
                <description>ICU bradycardia reported as Heart rate &lt; 60 beats/min</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This single center study with restrictive inclusion may place some limitations on generalizability.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Balachundhar Subramaniam</name_or_title>
      <organization>Beth Israel Deaconess Medical Center</organization>
      <phone>6176320706 ext 6176320706</phone>
      <email>bsubrama@bidmc.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

